Multi-Omics Pan-Cancer Profiling of Unveils Its Prognostic Potential, Metabolic Regulation, and Immune Microenvironment Interactions.

This study systematically analyzed the expression and clinical significance of Hydroxysteroid 17-beta dehydrogenase type 10 () in 33 cancers by integrating TCGA, GTEx, and other multi-omics databases. was highly expressed in 14 cancers, like GBM and LGG, but low in 5, such as KIRC. Its expression correlated closely with overall survival (OS) and disease-free survival (DFS). In GBM-LGG, LGG, and other cancers, high expression was linked to lower survival rates, indicating that it could be an independent prognostic marker. also had a two-way relationship with the tumor's immune microenvironment. In cancers such as GBM-LGG, high expression correlated positively with immune/stromal scores. However, in most cancers like LUAD, it was negatively associated with B- and T-cell infiltration. Epigenetic analysis showed that low methylation in the promoter region might drive its high expression in tumors such as SARC, and specific methylation sites (e.g., CG26323797) were significantly related to patient survival. Functional enrichment analysis revealed that participated in tumor progression by regulating oxidative phosphorylation, mitochondrial metabolism, and RNA methylation. Single-cell and spatial transcriptome data further demonstrated that had a cell-type-specific expression pattern in colorectal cancer. This study provides a theoretical basis for as a pan-cancer prognostic marker and therapeutic target.